BSP:H1OL34 (USA)
Business Description
Hologic Inc
NAICS : 334517
SIC : 3844
250 Campus Drive, Marlborough, MA, USA, 01752
Description
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.84 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | 1.19 | |||||
Interest Coverage | 20.34 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.35 | |||||
Beneish M-Score | -3.24 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.8 | |||||
3-Year EBITDA Growth Rate | 143.3 | |||||
3-Year FCF Growth Rate | 54.1 | |||||
3-Year Book Growth Rate | 22.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | -18.74 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | -10.44 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.6 | |||||
9-Day RSI | 33.15 | |||||
14-Day RSI | 36.4 | |||||
6-1 Month Momentum % | -11.78 | |||||
12-1 Month Momentum % | -7.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.91 | |||||
Quick Ratio | 3.32 | |||||
Cash Ratio | 2.37 | |||||
Days Inventory | 100.23 | |||||
Days Sales Outstanding | 61.15 | |||||
Days Payable | 40.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.1 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.35 | |||||
Operating Margin % | 36.47 | |||||
Net Margin % | 28.93 | |||||
ROE % | 33.74 | |||||
ROA % | 16.56 | |||||
ROIC % | 22.83 | |||||
ROC (Joel Greenblatt) % | 149.85 | |||||
ROCE % | 24.8 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 12.31 | |||||
Forward PE Ratio | 19.31 | |||||
PE Ratio without NRI | 12.31 | |||||
Shiller PE Ratio | 45.07 | |||||
Price-to-Owner-Earnings | 8.29 | |||||
PEG Ratio | 0.69 | |||||
PS Ratio | 3.56 | |||||
PB Ratio | 3.64 | |||||
Price-to-Tangible-Book | 66.11 | |||||
Price-to-Free-Cash-Flow | 8.07 | |||||
Price-to-Operating-Cash-Flow | 7.68 | |||||
EV-to-EBIT | 9.59 | |||||
EV-to-Forward-EBIT | 15.34 | |||||
EV-to-EBITDA | 7.82 | |||||
EV-to-Forward-EBITDA | 12.96 | |||||
EV-to-Revenue | 3.58 | |||||
EV-to-Forward-Revenue | 4.25 | |||||
EV-to-FCF | 8.11 | |||||
Price-to-Projected-FCF | 1.06 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.5 | |||||
Price-to-Graham-Number | 6.01 | |||||
Earnings Yield (Greenblatt) % | 10.43 | |||||
Forward Rate of Return (Yacktman) % | 25.66 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 27,475.201 | ||
EPS (TTM) (R$) | 31.285 | ||
Beta | 0 | ||
Volatility % | 15.51 | ||
14-Day RSI | 36.4 | ||
14-Day ATR (R$) | 1.080083 | ||
20-Day SMA (R$) | 373.954 | ||
12-1 Month Momentum % | -7.4 | ||
52-Week Range (R$) | 368.9 - 423 | ||
Shares Outstanding (Mil) | 249.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hologic Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |